Compare MC & BCPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MC | BCPC |
|---|---|---|
| Founded | 2007 | 1967 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Major Chemicals |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 4.8B |
| IPO Year | 2014 | N/A |
| Metric | MC | BCPC |
|---|---|---|
| Price | $68.98 | $153.74 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 2 |
| Target Price | $73.75 | ★ $176.00 |
| AVG Volume (30 Days) | ★ 824.8K | 219.6K |
| Earning Date | 02-04-2026 | 10-21-2025 |
| Dividend Yield | ★ 3.69% | 0.62% |
| EPS Growth | ★ 446.16 | 22.48 |
| EPS | 3.17 | ★ 4.57 |
| Revenue | ★ $1,467,580,000.00 | $1,013,548,000.00 |
| Revenue This Year | $27.08 | $10.41 |
| Revenue Next Year | $17.26 | $5.89 |
| P/E Ratio | ★ $22.23 | $33.82 |
| Revenue Growth | ★ 51.19 | 7.55 |
| 52 Week Low | $47.00 | $139.17 |
| 52 Week High | $82.89 | $177.40 |
| Indicator | MC | BCPC |
|---|---|---|
| Relative Strength Index (RSI) | 50.59 | 44.26 |
| Support Level | $69.51 | $155.62 |
| Resistance Level | $71.78 | $158.59 |
| Average True Range (ATR) | 1.53 | 3.36 |
| MACD | -0.12 | -0.31 |
| Stochastic Oscillator | 11.83 | 7.94 |
Moelis & Co is an independent investment bank that provides strategic and financial advice to a diverse client base, including corporations, financial sponsors, governments, and sovereign wealth funds. The company assists its clients in achieving their strategic goals by offering comprehensive, globally integrated financial advisory services across all industry sectors. It also advises clients on their critical decisions, including mergers and acquisitions, recapitalizations and restructurings, capital markets transactions, and other corporate finance matters. it generates revenue from advisory transactions. The firm derives a majority of its revenue from the United States followed by Europe and the rest of the World.
Balchem Corp is engaged in the development, manufacture, and marketing of specialty performance ingredients and products for various industries. The company's reportable segments are; Human Nutrition and Health, which generates maximum revenue, and provides human-grade choline nutrients and mineral amino acid chelated products through this segment for nutrition and health applications; Animal Nutrition and Health, which provides nutritional products derived from its microencapsulation and chelation technologies in addition to the essential nutrient choline chloride; and the Specialty Products segment includes re-packaging and distributing several performance gases and chemicals. Geographically, the company derives its key revenue from the United States and the rest from foreign countries.